Gapping up
In reaction to strong earnings/guidance:
- CDMO +15.5%, CASY +4.4%, SONC +1.1%
M&A news:
- IDTI +11.4% (Integrated Device to be acquired by Renesas (RNECF) for $49.00/share in cash, or approximately $6.7 bln)
- XL +1% (after AXA [AXAHY] obtained regulatory approvals for the acquisition of XL Group that is now expected to close on September 12)
Select names showing strength related to impact of hurricane:
- BECN +2.1%, GNRC +1.8%, HD +0.9%, LOW +0.9%, TSCO +0.6%, BGG +0.6%
Other news:
- SIGA +13.5% (awarded BARDA contract for TPOXX valued at up to $629 mln)
- ACRX +6.2% (announces date of FDA advisory committee meeting for Dsuvia)
- SSTI +5.5% (after making new all-time highs and closing up 4% on the day)
- NTNX +3.2% (closed the largest deal in company history in Q4 of fiscal 2018, worth more than $20m with an agency in the U.S. Department of Defense)
- SB +2.8% (Safe Bulkers agrees with Cosco Shipping Heavy Industry Co. Ltd. to install Alfa Laval PureSOx Scrubbers)
- HTHT +2.4% (reiterates corporate policy and commitment of ensuring the safety and privacy of customer information)
- TRVN +2.3% (FDA scheduled Oct 11 meeting of the Anesthetic and Analgesic Drug Products Advisory Committee to discuss safety/efficacy of oliceridine injection for the management of acute pain)
- CRSP +1% (CRISPR Therapeutics, Intellia (NTLA) and Caribou Biosciences provide update on appeal upholding the PTO ruling in interference proceeding relating to CRISPR/Cas9 genome editing technology ), .
Analyst comments:
- RUN +3.8% (upgraded to Buy from Neutral at BofA/Merrill)
- SNAP +2.3% (upgraded to Outperform from Neutral at Wedbush)
- EQNR +1.9% (upgraded to Equal Weight from Underweight at Barclays)
- BBDC +1.5% (upgraded to Outperform from Mkt Perform at Raymond James)
- DRI +1.2% (upgraded to Buy from Neutral at Goldman)
- CZR +1% (initiated with a Outperform at Credit Suisse)
- NKE +0.9% (upgraded to Buy from Hold at Canaccord Genuity)
- ENDP +0.8% (upgraded to Neutral from Sell at Goldman)